Acute Lymphoblastic Leukemia

$469,989U01FY2008GMNIH

University Of Chicago, Chicago IL

Investigators

Linked publications & trials

Paper 38438359 Paper 34149004 Paper 32378051 Paper 32122921 Paper 31274208 Paper 30657858 Paper 30564130 Paper 30205839 Paper 29335598 Paper 29050522 Paper 28847918 Paper 28698977 Paper 28645005 Paper 28391009 Paper 28373166 Paper 28335481 Paper 27845419 Paper 27654937 Paper 27224917 Paper 27143689 Paper 26873729 Paper 26840454 Paper 26828329 Paper 26774046 Paper 26417955 Paper 26318634 Paper 26296641 Paper 26258848 Paper 26178744 Paper 26160883 Paper 26053558 Paper 26015512 Paper 25962919 Paper 25870101 Paper 25869015 Paper 25818895 Paper 25724890 Paper 25710658 Paper 25689802 Paper 25564375 Paper 25506832 Paper 25490892 Paper 25449594 Paper 25417775 Paper 25411163 Paper 25307299 Paper 25277794 Paper 25270638 Paper 25243102 Paper 25229481 Paper 25221879 Paper 25119182 Paper 25019052 Paper 24980783 Paper 24958824 Paper 24943591 Paper 24879639 Paper 24799323 Paper 24739237 Paper 24711425 Paper 24699530 Paper 24699359 Paper 24637941 Paper 24623533 Paper 24609542 Paper 24595012 Paper 24580837 Paper 24568970 Paper 24549002 Paper 24520339 Paper 24513692 Paper 24367505 Paper 24300566 Paper 24241639 Paper 24186849 Paper 24185610 Paper 24084763 Paper 24048068 Paper 24024897 Paper 24024891 Paper 23922447 Paper 23872831 Paper 23824859 Paper 23792949 Paper 23758991 Paper 23755828 Paper 23755062 Paper 23720496 Paper 23556440 Paper 23538338 Paper 23508821 Paper 23394393 Paper 23355459 Paper 23340433 Paper 23243203 Paper 23204130 Paper 23188748 Paper 23188068 Paper 23183705 Paper 23133393

Abstract

Our studies in CRC will include a continuation of our work on irinotecan, as well as studies of newer targeted agents involving the EGFR and VEGF pathways. This will include studies in silico, in vitro, clinical studies at UC, and pharmacogenetic studies associated with large-scale clinical trials in the NCI-funded Cooperative Group, CALGB. hi addition, our plans include collaborative studies within the PGRN with CREATE, PMT, and PAT (Figure 12). Furthermore, this Project will interact closely with other PAAR Projects, particularly the CS Project.

View original record on NIH RePORTER →